Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Obesity, Diabetes and the Metabolic Syndrome
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Partnering with Patients: Building Effective Communication and Support in HF Care
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?